Persistence of cytogenetic damage induced by alkylating antineoplastic drug phopurinum in human lymphocytes in vivo and in vitro.
Sister chromatid exchanges (SCEs) and structural chromosome aberrations (CAs) induced by cytostatic drug phopurinum in vivo and in vitro were studied in human lymphocytes. Phopurinum was found to cause a significant increase of CAs in lymphocytes of patients undergoing cytostatic therapy. Increased CA rates, however, declined rapidly after the cessation of treatment. This decline observed in vivo is in agreement with experimental results obtained in vitro, where it is found that the induction of SCEs and CAs occur only during the 1st cell cycle after pulse-treatment as G1 stage with phopurinum. Thus, phopurinum induced short-lived DNA damage both experimentally and in vivo.
Lazutka
J R
JR
Ecological Genetics Laboratory, Vilnius University, Lithuania.
Slapsyte
G
G
D000970:Antineoplastic Agents / Q000633:toxicity*; D001388:Aziridines; D002869:Chromosome Aberrations / Q000235:genetics; D004249:DNA Damage; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects* / Q000502:physiology; D008677:Metaphase / Q000187:drug effects; D008875:Middle Aged; D009943:Organophosphorus Compounds / Q000633:toxicity*; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy; D011687:Purines / Q000633:toxicity*; D012044:Regression Analysis; D012854:Sister Chromatid Exchange / Q000187:drug effects
D000970:Antineoplastic Agents; D001388:Aziridines; D009943:Organophosphorus Compounds; D011687:Purines; C015893:pumitepa